间皮素是急性髓系白血病新型细胞表面疾病标志物及潜在治疗靶点
该研究分析2051例儿童及年轻成人AML转录组,发现间皮素(MSLN)在36%的AML中高表达而在正常骨髓中几乎不表达。MSLN表达与KMT2A重排、核心结合因子融合及髓外疾病相关,其靶向抗体药物偶联物在临床前模型中显示靶向依赖性细胞毒作用。
要点
- MSLN在36%的AML中高表达,正常骨髓几乎不表达。
- MSLN表达与KMT2A重排、CBF融合及髓外疾病显著相关。
- MSLN靶向ADC在临床前模型中显示有效细胞毒作用。
核心结论
- MSLN在显著比例的AML患者中表达,是有前景的诊断和治疗靶点。
- MSLN靶向治疗策略包括ADC值得进一步临床研究。
研究设计与样本
- 分析2051例儿童和年轻成人AML及正常骨髓标本的转录组。
- 通过qRT-PCR验证转录本,多维流式细胞术确认细胞表面蛋白表达。
- 在体外、体内及患者来源异种移植模型中评估MSLN靶向ADC的临床前疗效。
主要发现
- MSLN在36%的AML队列中高过表达(范围5-1077.6 TPM),正常骨髓中几乎缺失(范围0.1-10.7 TPM)。
- MSLN表达与KMT2A重排(P < .001)、inv(16)/t(16;16)(P < .001)、t(8;21)(P < .001)及髓外疾病(P = .001)相关。
- MSLN表达与启动子低甲基化相关。
- 诊断血清标本中可检测到可溶性MSLN。
- MSLN靶向ADC anetumab ravtansine和anti-MSLN-DGN462在MSLN+ AML中产生强效靶向依赖性细胞毒作用。
临床怎么用
- MSLN可作为AML诊断标志物,尤其在与KMT2A重排、CBF融合或髓外疾病相关的患者中。
- MSLN靶向ADC是有潜力的治疗策略,需进一步临床研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In an effort to identify acute myeloid leukemia (AML)-restricted targets for therapeutic development in AML, we analyzed the transcriptomes of 2051 children and young adults with AML and compared the expression profile with normal marrow specimens. This analysis identified a large cohort of AML-restricted genes with high expression in AML, but low to no expression in normal hematopoiesis. Mesothelin (MSLN), a known therapeutic target in solid tumors, was shown to be highly overexpressed in 36% of the AML cohort (range, 5-1077.6 transcripts per million [TPM]) and virtually absent in normal marrow (range, 0.1-10.7 TPM). We verified MSLN transcript expression by quantitative reverse transcription polymerase chain reaction, confirmed cell surface protein expression on leukemic blasts by multidimensional flow cytometry, and demonstrated that MSLN expression was associated with promoter hypomethylation. MSLN was highly expressed in patients with KMT2A rearrangements (P < .001), core-binding factor fusions [inv(16)/t(16;16), P < .001; t(8;21), P < .001], and extramedullary disease (P = .001). We also demonstrated the presence of soluble MSLN in diagnostic serum specimens using an MSLN-directed enzyme-linked immunosorbent assay. In vitro and in vivo preclinical efficacy of the MSLN-directed antibody-drug conjugates (ADCs) anetumab ravtansine and anti-MSLN-DGN462 were evaluated in MSLN+ leukemia cell lines in vitro and in vivo, as well as in patient-derived xenografts. Treatment with ADCs resulted in potent target-dependent cytotoxicity in MSLN+ AML. In this study, we demonstrate that MSLN is expressed in a significant proportion of patients with AML and holds significant promise as a diagnostic and therapeutic target in AML, and that MSLN-directed therapeutic strategies, including ADCs, warrant further clinical investigation.
引用
- Kaeding AJ, Barwe SP, Gopalakrishnapillai A, et al. Mesothelin is a novel cell surface disease marker and potential therapeutic target in acute myeloid leukemia. Blood Adv. 2021. PMID: 33938941. doi:10.1182/bloodadvances.2021004424
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。